Aligos Therapeutics Inc. shares advanced 7.6% in pre-market trading to $6.55 on Tuesday, extending gains after the company reported stronger-than-anticipated financial results and operational progress.
The clinical-stage biotechnology firm, listed under ticker ALGS, released second-quarter 2026 financial figures in early August that showed a significantly reduced net loss and earnings per share well above analyst expectations. The company also confirmed non-dilutive funding from a Greater China licensing agreement for its experimental antiviral pevifoscorvir sodium, which bolstered its balance sheet.
In clinical development, Aligos announced the full enrollment of patients in its Phase 2 B-SUPREME study, which is evaluating pevifoscorvir sodium as a treatment for chronic hepatitis B virus infection. The drug candidate targets a high-unmet need in a large patient population, with interim data from the study expected later this year.
The broader equity market showed modest declines, with the NASDAQ down 0.6%, the S&P 500 off 0.2%, and the Dow down 0.1% during regular trading hours.
Aligos’ stock remains substantially below its 52-week high of $13.69, reflecting both its early-stage pipeline and the inherent volatility of biotech equities.
